Derrick Tesseneer, MD
Nephrology · Flowood, MSNPI 1588875363
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 268 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations.
Across 268 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$963
- Amgen$511
- Akebia Therapeutics Inc$413
- Mallinckrodt Hospital Products Inc.$356
- Vifor Pharma, Inc.$340
- Bayer$324
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,16696%
- Education$2354%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 45 | $963 |
| Amgen(2 entities) | 26 | $511 |
| Akebia Therapeutics Inc | 24 | $413 |
| Mallinckrodt Hospital Products Inc. | 14 | $356 |
| Vifor Pharma, Inc. | 18 | $340 |
| Bayer | 17 | $324 |
| Otsuka America Pharmaceutical, Inc. | 15 | $315 |
| Calliditas Therapeutics US Inc. | 12 | $314 |
| OPKO Pharmaceuticals, LLC | 18 | $278 |
| Novartis | 10 | $252 |
| Fresenius USA Marketing, Inc. | 14 | $230 |
| Aurinia Pharma U.S., Inc. | 10 | $201 |
| ANI Pharmaceuticals, Inc. | 8 | $144 |
| Ardelyx, Inc. | 6 | $114 |
| Nxstage Medical, Inc. | 1 | $102 |
| Travere Therapeutics, Inc. | 5 | $81 |
| Boehringer Ingelheim | 4 | $66 |
| Daiichi Sankyo Inc. | 3 | $62 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $57 |
| Vanda Pharmaceuticals Inc. | 3 | $56 |
| Lilly USA, LLC | 3 | $51 |
| GSK | 3 | $51 |
| Genentech USA, Inc. | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$125
- NXSTAGE SYSTEM ONE$102
How this compares
$5,401 in reported general payments places this provider in the 85th percentile of 105 nephrology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 62 | $147,207 |
| AuryxiaFerric Citrate | 56 | $91,529 |
| FarxigaDapagliflozin Propanediol | 51 | $40,466 |
| JardianceEmpagliflozin | 56 | $39,362 |
| RayaldeeCalcifediol | 21 | $24,923 |
| LokelmaSodium Zirconium Cyclosilicate | 31 | $24,372 |
| VeltassaPatiromer Calcium Sorbitex | 19 | $18,158 |
| KerendiaFinerenone | 13 | $9,725 |
| Sevelamer Carbonate | 39 | $4,232 |
| Nifedipine ErNifedipine | 22 | $1,556 |
| Midodrine Hcl | 28 | $1,132 |
| Calcitriol | 103 | $970 |
| Hydralazine Hcl | 64 | $584 |
| Spironolactone | 45 | $422 |
| Amlodipine Besylate | 92 | $317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $230 | $147,20762 claims |
| Akebia Therapeutics IncAuryxia | $413 | $91,52956 claims |
| AstraZenecaFarxiga, Lokelma | $963 | $64,83882 claims |
| Boehringer IngelheimJardiance | $66 | $39,36256 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $278 | $24,92321 claims |
| BayerKerendia | $324 | $9,72513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 105 nephrology providers in Mississippi.
Other nephrology in Flowood
- Mohit AhujaFlowood$427K
- Steven WagnerFlowood$6K
- Francis PhillippiFlowood$6K
- Daphne BilbrewFlowood$6K
- Ami PatelFlowood$5K
- Karthikeyan VenkatachalamFlowood$5K
- Lee FergusonFlowood$4K
- Lindsey NorrisFlowood$4K
- Mark KleinFlowood$3K
- Naveen SandhuFlowood$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.